Combined modality therapy for cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology

Volumn 34, Issue 6, 1996, Pages 1022-1029

  Duvic, Madeleine ^a,b   Lemak, Noreen A ^a   Redman, John R ^a   Eifel, Patricia J ^a   Tucker, Susan L ^a   Cabanillas, Fernando F ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; METHOTREXATE; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CLINICAL ARTICLE; DIARRHEA; DRY SKIN; ELECTRON BEAM; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAINTENANCE THERAPY; MALE; MYCOSIS FUNGOIDES; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN LYMPHOMA; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TOPICAL DRUG ADMINISTRATION;

EID: 0029982190     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90282-0     Document Type: Article

References (28)

1. Abel EA, Wood GS, Hoppe RT. Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. CA Cancer J Clin 1993;43:93-115.
2. Wood GS, Haeffner A, Dummer R, et al. Molecular biology techniques for the diagnosis of cutaneous T-cell lymphoma. Dermatol Clin 1994;12:231-41.
3. Heald P, Yan SL, Edelson R. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T cell lymphoma. Arch Dermatol 1994;130:198-203.
4. Pancake BA, Zucker-Franklin D, Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. J Clin Invest 1995;95:547-54.
5. Epstein EH Jr, Levin DL, Croft JD Jr, et al. Mycosis fungoides: survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 1972;51:61-72.
6. Lamberg SI, Green SB, Byar DP, et al. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 1984;100: 187-92.
7. Vonderheid EC, Diamond LW, van Vloten WA, et al. Lymph node classification systems in cutaneous T cell lymphoma: evidence for the utility of the working formulation of non-Hodgkin's lymphomas for clinical usage. Cancer 1994;73:207-18.
8. Sausvule EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.
9. Vonderheid EC, Van Scott EJ, Wallner PE, et al. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep 1979;63: 681-9.
10. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979;63:691-700.
11. Winkler CF, Bunn PA JR. Cutaneous T-cell lymphoma: a review. Crit Rev Oncol Hematol 1983;1:49-92.
12. Winkler CF, Sausville EA, Hide DC, et al. Combined modality treatment of cutaneous T cell lymphoma:results of a 6-year follow-up. J Clin Oncol 1986;4:1094-100.
13. Braverman IM, Yager NB, Chen M, et al. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 1987;16:45-60.
14. Griem ML, Tokars RP, Petras V, et al. Combined therapy for patients with mycosis fungoides. Cancer Treat Rep 1979;63:655-70.
15. Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994;121:592-602.
16. Covelli A, Cavalieri R, Coppola G, et al. Recombinant leucocyte A interferon (IFN-rA) as initial therapy in mycosis fungoides (MF) and Sézary syndrome (SS) [abstract]. Proc Am Soc Clin Oncol 1987;6:189.
17. Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.
18. Hoppe RT, Abel EA, Deneau DG, et al. Mycosis fungoidesmanagement with topical nitrogen mustard. J Clin Oncol 1987;5:1796-803.
19. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:416-28.
20. Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:203-7.
21. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990;22:381-401.
22. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
23. Bunn PA Jr, Foon KA, Hide DC, et al. Recombinant leucocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-7.
24. Karnofsky DA. Meaningful clinical classification of therapeutic response to anti-cancer drugs. Clin Pharmacol Ther 1961;2:709-12.
25. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.
26. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4:234-43.
27. Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 1987;71:493-515.
28. Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995;13:257-63.